- A pharmaceutical composition comprising a solubilized SLC25A1 inhibitor for treating non-alcoholic fatty liver disease (NAFLD) has been shown to halt the evolution of non-alcoholic steatohepatitis (NASH) reverting steatosis, decrease inflammation, decreas
- The SLC25A1 inhibitor may be administered alone or in combination with a second therapeutic agent, such as a CCK receptor inhibitor, metformin, pioglitazone, vitamin E, or statin.
- The SLC25A1 can be administered in conjunction with other therapies for liver disease, for example, at the same time, prior to or after surgery, immunotherapy, transplant therapy, or other pharmacotherapy.
OVERVIEW
Georgetown University researchers have discovered a prospective drug treatment method that utilizes a SLC25A1 inhibitor to effectively treat NAFLD/NASH, diseases for which there are currently limited options for treatment.
BACKGROUND
NAFLD/NASH is predicted to become the most common cause of chronic liver disease and liver transplantation, with a current worldwide prevalence as high as 25%. Individuals affected by NASH are often obese and display insulin resistance and alterations in the lipid anabolic processes that ultimately lead to the deposition and accumulation of fat deposits in the liver (steatosis). The high levels of fats in both the liver and blood produce progressive liver damage, stimulate an inflammatory reaction that eventually leads to fibrosis and cirrhosis, and culminates in liver failure. There are currently limited options for the treatment of NAFLD/NASH.
Benefit
● The SLC25A1 inhibitor has been shown to halt the evolution of non-alcoholic steatohepatitis (NASH) reverting steatosis, decrease inflammation, decrease liver fibrosis, reduce hyperglycemia, and/or glucose intolerance, prevent the development or progression of cirrhosis and/or prevent the development of hepatocellular carcinoma (HCC) in a subject having NASH.
● It can be administered in an oral form, including capsule, tablet, pill, powder, and granules.
● Prolonged treatment in initial experiments has shown no toxicity.
Market Application
● A composition and method for treating NAFLD or NASH in a subject comprising administering an effective amount of a SLC25A1 inhibitor and a method of preparing the inhibitor composition are provided.
Publications
● Published patent application No. US 2022/0323389A1
● Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH (DOI: 10.1038/s41418-020-0491-6) (link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308387/)
Our mission is to advance GU’s innovations through strategic alliances and new venture creation, to facilitate the translation of research breakthroughs into tangible solutions, and to cultivate a dynamic and inclusive environment for entrepreneurship. We advance this mission in support of the GU community and for the benefit of society.
Create your free account to connect with Georgetown University and thousands of other innovative organizations and professionals worldwide
Send a request for information
to Georgetown University
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
